Join 250 fellow retina specialists for a unique educational experience in vitreoretinal medicine. This program is designed by and for retina specialists, offering updates on the most recent advances and their integration into everyday practice as well as insight into varying challenges, including the implementation of new diagnostic and treatment modalities. In a relaxed setting, faculty and attendees can discuss specific cases, new therapy and imaging techniques and the latest surgical strategies.
This program offers a non-concurrent schedule including: breakfast programs, general sessions, exhibit breaks, lunch programs and evening banyan tree sessions (all included in the single registration fee). Retina Program attendees are also able to attend sessions of interest under the Hawaiian Eye Comprehensive Ophthalmologist Program.
Upon completion of this activity, attendees should be better able to:
Explain new developments in the use of imaging, including its use in uveitis, optical coherence tomography (OCT) in the home, as well as teleretinal screening and its use in the management of retinal diseases.
Describe current trends in the management of macular degeneration, including the role of fluid in neovascular and non-neovascular AMD, the safe use of anti-VEGF therapy, and the use of gene therapy, implants, cell therapy and other novel treatments.
Explore new treatments for the management of age-related macular degeneration and other retinal vascular diseases.
Examine the evidence on current and emerging treatment paradigms for diabetic retinopathy (DR), proliferative and non-proliferative diabetic retinopathy (PDR and NPDR) and diabetic macular edema (DME).
Assess current and emerging approaches for the treatment of retinal vascular occlusions.
Review current trends in the management of pediatric retinal disorders.
Summarize new management concepts in vitreoretinal surgery, including the use of surgical instrumentation, achieving sterility, and management of retinal detachment, macular hole, congenital optic nerve anomalies, and other vitreoretinopathies.
Describe current diagnostic modalities as well as management options for retinoblastoma, melanoma, and other ocular tumors.
Assess the changing ophthalmic practice environment and how providers can improve patient care amid the COVID-19 era.
This continuing medical education activity is provided by
ACCREDITATION: Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION: Vindico Medical Education designates this live activity for a maximum of 24 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
INTERNATIONAL NOTICE: This educational activity is designated for AMA PRA Category 1 Credit(s)™ for all US physicians. US physicians will receive a CME certificate and non-US physicians should contact their respective organizations for reciprocity of credit.
FACULTY/PLANNER DISCLOSURE POLICY: In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to mitigate and disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.
NOTICE: Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance.